COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023)

COSCIENS Biopharma (TSE:CSCI) Full Year 2024 Results

Key Financial Results

• Revenue: US$9.59m (up 34% from FY 2023).
• Net loss: US$15.3m (loss widened by 339% from FY 2023).
• US$5.93 loss per share (further deteriorated from US$1.89 loss in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

CSCI Products In Clinical Trials

• Phase I: 1.
• Phase III: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

COSCIENS Biopharma shares are up 13% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with COSCIENS Biopharma (at least 4 which are concerning), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.